AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Vasoactive intestinal polypeptide receptor 1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for receptors.

 Fig. 1. The sreening workflow of Receptor.AI

It includes extensive molecular simulations of the receptor in its native membrane environment and the ensemble virtual screening accounting for its conformational mobility. In the case of dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets are determined on and between the subunits to cover the whole spectrum of possible mechanisms of action.

Our library distinguishes itself through several key aspects:

  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

P32241

UPID:

VIPR1_HUMAN

Alternative names:

Pituitary adenylate cyclase-activating polypeptide type II receptor; VPAC1

Alternative UPACC:

P32241; A5JUT9; B3KPV1; B4DEB5; B4DGI4; F5H1F5; G3V0I1; Q15871; Q6P2M6

Background:

Vasoactive intestinal polypeptide receptor 1 (VIPR1), also known as VPAC1, is a critical receptor that binds vasoactive intestinal polypeptide (VIP) with high affinity. Its activity is mediated through G proteins that activate adenylyl cyclase, leading to increased levels of cyclic AMP. VIPR1 shows a preference for VIP over pituitary adenylate cyclase-activating polypeptide (PACAP-27 and PACAP-38), highlighting its specificity in cellular signaling pathways.

Therapeutic significance:

Understanding the role of Vasoactive intestinal polypeptide receptor 1 could open doors to potential therapeutic strategies. Its involvement in cyclic AMP signaling pathways suggests its potential impact on diseases where these pathways are dysregulated. Exploring VIPR1's functions and interactions could lead to novel treatments for such conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.